COVID

GastroMuñoz

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Clinical Characteristics of Patients With SARS-CoV-2 (COVID-19) Infection in Guayaquil, Ecuador: COVID-EC Study

To know the clinical characteristics of patients with COVID-19 treated in hospitals in Guayaquil, Ecuador.

Establish the prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death.

To determine the clinical characteristics of the patients with the worst prognosis.

Relate, at least retrospectively, the relationship that may exist between the different treatments and the prognosis.

Jorge Carriel M.

Physician

Hospital San Carlos, Madrid

Universidad Catolica Santiago de Guayaquil

Angiotensin-(1-7) infusion (venous) of 0.2 mcg/Kg/h for 48h

Coronavirus

Respiratory Failure

Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere

SARS-CoV-2

endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%

Angiotensin 1-7

infusion of NaCl 0.9% without diluted peptide in it

Placebos

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

composite outcome of mortality and necessity of mechanical ventilation

number of days free from intensive care unit

PaO2/FiO2 changes during drug administration

including IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, TNF-alpha, interferon gamma

phase 2b = principal safety outcome; phase 3 = secondary outcome

Erasme University Hospital

Fonds Erasme pour la Recherche Médicale

Randomized, controlled, investigator initiated, phase II/phase III seamless, adaptive, single blinded, interventional trial to evaluate the efficacy, safety and clinical impact of intravenous Ang-(1-7) infusion compared to standard treatment in ICU patients with severe respiratory failure associated with COVID-19. This study will be conducted initially in one center (Erasme Hospital, Belgium), but other sites will be allowed to join if: Number of expected patients with COVID related ARF ≥ 10, experience in treatment of ARDS patients (> 25/year), including prone positioning ,availability of the equipment required to provide the blood sample processing and storage. We planned a first phase of the study where 30 patients will be randomly receiving Ang-(1-7) or placebo to confirm the safety. The Final power calculation will be reassessed after 30 included patients (i.e. 15 in each arm), in line with a preplanned expected total number of patients needed of 60.

Randomization will be performed using sealed envelopes with a ratio of 1:1 including information on treatment assignment and a five-digit number, which will be open by the person responsible for drug constitution. Each vial or syringe will be then labeled with the randomly allocated number it will be assigned to the nursing personnel. The doctors and nurses administering the drugs, as well as the local investigators and research personnel who collected data, were unaware of the treatment assignments.

Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.

Andriol Testocaps

Camry Medical Centre

Frontier Medical Associates (Ubi) Pte Ltd

Everhealth Medical Centre

Frontier Medical Associates (Buangkok Cresent) Pte Ltd

Frontier Medical Associates (AMK) Pte Ltd

EJ Tan Clinic & Surgery

Everhealth Family Clinic & Surgery

Bukit Batok Medical Clinic

Princeton Family Clinic Pte Ltd

The Edinburgh Clinic

Frontier Medical Associates (Woodlands) Pte Ltd

Frontier Medical Associates (Yishun) Pte Ltd

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes: OTEST

The primary aim is to assess the effect of oral Testosterone Supplementation on percent change in HbA1c in Type 2 Diabetes Mellitus Chinese males in Singapore over a 90-day study period.

The secondary aim is to assess the effects of site, eugonadism and hypogonadism, and the prognostic relevance of baseline levels of HbA1c, total testosterone, PSA, IPSS, haemoglobin and haematocrit on 90-day change and percent change from baseline in HbA1c under the study Testosterone Supplementation regimen.

venous thrombosis/kalis

COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial

The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu